Free Trial
NYSE:BDX

Becton, Dickinson and Company Q2 2025 Earnings Report

Becton, Dickinson and Company logo
$206.89 +0.45 (+0.22%)
As of 03:59 PM Eastern

Becton, Dickinson and Company EPS Results

Actual EPS
N/A
Consensus EPS
$3.28
Beat/Miss
N/A
One Year Ago EPS
N/A

Becton, Dickinson and Company Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.35 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Becton, Dickinson and Company Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 1, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Becton, Dickinson and Company Earnings Headlines

Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.
BD Board Declares Dividend
Becton, Dickinson and Company: It's Wait And See For Me
See More Becton, Dickinson and Company Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Becton, Dickinson and Company? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Becton, Dickinson and Company and other key companies, straight to your email.

About Becton, Dickinson and Company

Becton, Dickinson and Company (NYSE:BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

View Becton, Dickinson and Company Profile

More Earnings Resources from MarketBeat